Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-20-deoxycytidine in solid tumor cells

Molecular Cancer Therapeutics

Volumn 12, Issue 10, 2013, Pages 2226-2236

  Venturelli, Sascha ^a   Berger, Alexander ^a,b   Weiland, Timo ^a   Essmann, Frank ^a   Waibel, Michaela ^e   Nuebling, Tina ^a   Häcker, Sabine ^c   Schenk, Martin ^a   Schulze Osthoff, Klaus ^a,b   Salih, Helmut R ^a   Fulda, Simone ^d   Sipos, Bence ^a   Johnstone, Ricky W ^e   Lauer, Ulrich M ^a   Bitzer, Michael ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CASPASE; DNA METHYLTRANSFERASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 8; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL STRAIN HEPG2; CELL VIABILITY; CHORIOALLANTOIS; COLON CANCER; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; EPIGENETICS; HEPATOMA CELL; HUMAN; HUMAN CELL; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; SOLID TUMOR; TUMOR XENOGRAFT;

APOPTOSIS; AZACITIDINE; CELL AGING; CELL LINE, TUMOR; CELL PROLIFERATION; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA BREAKS, DOUBLE-STRANDED; DNA METHYLATION; HEP G2 CELLS; HUMANS; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84885665873     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0137     Document Type: Article

References (49)

1. Tohyama K. New treatment strategy of the myelodysplastic syndromes. Curr Pharm Des 2012;18: 3147-48.
2. Griffiths EA, Gore SD. Epigenetic therapies in MDS and AML. Adv Exp Med Biol 2013;754: 253-83.
3. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008;123: 8-13.
4. Venturelli S, Berger A, Weiland T, Zimmermann M, Häcker S, Peter C, et al. Dual antitumour effect of 5-azacytidine by inducing a breakdown of resistance-mediating factors and epigenetic modulation. Gut 2011;60: 156-65.
5. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002;62: 1876-83.
6. Lleonart ME, Artero-Castro A, Kondoh H. Senescence induction: a possible cancer therapy. Mol Cancer 2009;8:3.
7. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007;130: 223-33.
8. Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer Inst 2010;102: 1536-46.
9. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 2010;10: 51-7.
10. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol 2011;192: 547-56.
11. Timmermann S, Hinds PW, Münger K. Re-expression of endogenous p16ink4a in oral squamous cell carcinoma lines by 5-aza-20-deoxycytidine treatment induces a senescence-like state. Oncogene 1998;17: 3445-53.
12. Suh SI, Pyun HY, Cho JW, Baek WK, Park JB, Kwon T, et al. 5-Aza-20- deoxycytidine leads to down-regulation of aberrant p16INK4A RNA transcripts and restores the functional retinoblastoma protein pathway in hepatocellular carcinoma cell lines. Cancer Lett 2000;160: 81-8.
13. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, et al. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res 2008;68: 7956-65.
14. Xing JZ, Zhu L, Jackson JA, Gabos S, Sun XJ, Wang XB, et al. Dynamic monitoring of cytotoxicity on microelectronic sensors. Chem Res Toxicol 2005;18: 154-61.
15. Weiland T, Berger A, Essmann F, Lauer UM, Bitzer M, Venturelli S. Kinetic tracking of therapy-induced senescence using the real-time cell analyzer single plate system. Assay Drug Dev Technol 2012;10: 289-95.
16. Cichowski K, Hahn WC. Unexpected pieces to the senescence puzzle. Cell 2008;133: 958-61.
17. Lee TK, Lau TC, Ng IO. Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemother Pharmacol 2002;49: 78-86.
18. Lachner M, O'Carroll D, Rea S, Mechtler K, Jenuwein T. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 2001;410: 116-20.
19. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005;436: 660-5.
20. Zhang R, Chen W, Adams PD. Molecular dissection of formation of senescence-associated hetero-chromatin foci. Mol Cell Biol 2007;27: 2343-58.
21. Kuilman T, Peeper DS. Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer 2009;9: 81-94.
22. Uekawa N, Nishikimi A, Isobe K, Iwakura Y, Maruyama M. Involvement of IL-1 family proteins in p38 linked cellular senescence of mouse embryonic fibroblasts. FEBS Lett 2004;575: 30-4.
23. Gorgoulis VG, Pratsinis H, Zacharatos P, Demoliou C, Sigala F, Asimacopoulos PJ, et al. p53-dependent ICAM-1 overexpression in senescent human cells identified in atherosclerotic lesions. Lab Invest 2005;85: 502-11.
24. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008;133: 1019-31.
25. Orjalo AV, Bhaumik D, Gengler BK, Scott GK, Campisi J. Cell surfacebound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc Natl Acad Sci U S A 2009; 106: 17031-6.
26. Holden PR, James NH, Brooks AN, Roberts RA, Kimber I, Pennie WD. Identification of a possible association between carbon tetrachlorideinduced hepatotoxicity and interleukin-8 expression. J Biochem Mol Toxicol 2000;14: 283-90.
27. Hagimoto N, Kuwano K, Kawasaki M, Yoshimi M, Kaneko Y, Kunitake R, et al. Induction of interleukin-8 secretion and apoptosis in bronchiolar epithelial cells by Fas ligation. Am J Respir Cell Mol Biol 1999;21: 436-45.
28. Joshi-Barve S, Barve SS, Butt W, Klein J, McClain CJ. Inhibition of proteasome function leads to NF-kappaB-independent IL-8 expression in human hepatocytes. Hepatology 2003;38: 1178-87.
29. Cihák A. Biological effects of 5-azacytidine in eukaryotes. Oncology 1974;30:405.
30. Cihák A, Weiss JW, Pitot HC. Effects of 5-azacytidine on hepatic polyribosomes and maturation of ribosomal RNA. Acta Biol Med Ger 1974;33: 859-65.
31. Christman JK. 5-Azacytidine and 5-aza-20-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21: 5483-95.
32. Zhang W, Ji W, Yang J, Yang L, Chen W, Zhuang Z. Comparison of global DNA methylation profiles in replicative versus premature senescence. Life Sci 2008;83: 475-80.
33. Rücker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012;119: 2114-21.
34. Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, et al. The DNA methyltransferase inhibitors azacitidine, decitabine, and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009;23: 1019-28.
35. Hagemann S, Heil O, Lyko F, Brueckner B. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS ONE 2011;6:e17388.
36. Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE 2010;5:e9001.
37. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012;21: 430-46.
38. Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DNA methylation inhibitor 5-Aza-20-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol 2008;28: 752-71.
39. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445: 656-60.
40. Qian Y, Chen X. Tumor suppression by p53: making cells senescent. Histol Histopathol 2010;25: 515-26.
41. Cortvrindt R, Bernheim J, Buyssens N, Roobol K. 5-Azacytidine and 5- aza-20-deoxycytidine behave as different antineoplastic agents in B16 melanoma. Br J Cancer 1987;56: 261-5.
42. Snyder RD, Lachmann PJ. Differential effects of 5-azacytidine and 5- azadeoxycytidine on cytotoxicity, DNA-strand breaking and repair of X-ray-induced DNA damage in HeLa cells. Mutat Res 1989;226: 185-90.
43. Schmiedel BJ, Arélin V, Gruenebach F, Krusch M, Schmidt SM, Salih HR. Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int J Cancer 2011;128: 2911-22.
44. Buchi F, Spinelli E, Masala E, Gozzini A, Sanna A, Bosi A, et al. Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. Leuk Res 2012;36: 607-18.
45. Cohen MB, Glazer RI. Cytotoxicity and the inhibition of ribosomal RNA processing in human colon carcinoma cells. Mol Pharmacol 1985;27: 308-13.
46. Reuveni Y, Rosenthal LJ. Effect of azacytidine in SV40-infected BSC-1 cells. Intervirology 1979;11: 191-5.
47. Reuveni Y, Rosenthal LJ. Effect of 5-azacytidine on cytoplasmic ribosomal and messenger ribonucleic acids in BSC-1 cells. Antimicrob Agents Chemother 1979;15: 235-39.
48. Nguyen AN, Hollenbach PW, Richard N, Luna-Moran A, Brady H, Heise C, et al. Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines. Lung Cancer: Targets and Therapy 2010;1: 119-40.
49. Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 2006;66: 2794-800.